Literature DB >> 18785894

Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.

Sunil Bhandari1, Sarah Naudeer.   

Abstract

RATIONALE: The National Service Framework advocates correction of anaemia in patients with chronic kidney disease (CKD). Oral iron is insufficient, while intravenous (IV) supplementation replenishes and maintains iron stores. In Yorkshire numerous peripheral clinics exist to reduce travel for patients, but patients must travel to the main unit for IV iron therapy. Therefore an outpatient service in tandem with a routine clinic for administration of IV CosmoFer was created.
PURPOSE: To evaluate the feasibility and benefits of IV iron therapy in the outpatient clinic during active patient review for CKD patients.
DESIGN: A cross-sectional study of patients attending for total dose IV iron (n = 57) at a peripheral clinic. Iron was administered and monitored according to protocol by one of the clinic nurses with medical staff available in the adjoining room. Haemoglobin, ferritin and renal function were recorded pre-infusion and after 4-6 months. Results are given as medians/means +/- standard error.
RESULTS: A total of 76 IV infusions were carried out with no reported side effects or haemodynamic instability. Haemoglobin (median 10.9 vs. 11.3 g dL(-1), P = NS), creatinine and estimated glomerular filtration rate (eGFR) over the 6-month period remained stable. Serum ferritin rose significantly [80.9 +/- 6.2 vs. 186.4 +/- 18.2 g L(-1) (P < 0.001)]. Hospital time saved 380 day case bed hours, doctor hours saved 76 hours, and patient hours saved 3 hours/patient. Cost savings for TDI CosmoFer in peripheral clinic versus in centre therapy and versus sucrose, respectively, for 76 treatments was pound 5749.40 and pound 46,320.80 respectively.
CONCLUSION: We have demonstrated, in a resource-limited service, the feasibility and cost-effectiveness of a management care pathway for patients with CKD, in a peripheral clinic, to receive total dose IV CosmoFer without disruption of a functioning renal clinic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785894     DOI: 10.1111/j.1365-2753.2007.00932.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  8 in total

1.  Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Pantelis Oustamanolakis; Christos Karakoidas; Gerassimos J Mantzaris; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

2.  Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?

Authors:  Amy Barton Pai; Adinoyi O Garba
Journal:  J Blood Med       Date:  2012-08-29

3.  A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000.

Authors:  Sunil Bhandari
Journal:  Ther Clin Risk Manag       Date:  2011-03-15       Impact factor: 2.423

4.  Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice.

Authors:  Sunil Bhandari
Journal:  Ther Clin Risk Manag       Date:  2011-12-12       Impact factor: 2.423

5.  The safety of accelerated infusion versus standard rate infusion of low-molecular-weight iron dextran in patients with chronic kidney disease.

Authors:  Smeeta Sinha; Diana Y Y Chiu; George Peebles; Shabeer Kolakkat; Elizabeth Lamerton; Sean Fenwick; Philip A Kalra
Journal:  NDT Plus       Date:  2009-10

6.  Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).

Authors:  Ahmed Ziedan; Sunil Bhandari
Journal:  Trials       Date:  2019-04-04       Impact factor: 2.279

7.  Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care.

Authors:  Sunil Bhandari
Journal:  NDT Plus       Date:  2011-06

Review 8.  Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.

Authors:  Philip A Kalra; Sunil Bhandari
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.